Brand semaglutide
Sold by WellMedr · every brand semaglutide record
The register has not established whether this program ships a vial, a pen, or another form. That is a gap in our record, not a statement about the company.
What you actually pay
Per month
At least $1,399
| Medication · Ozempic, month-to-month | $1,399 |
|---|---|
| Consultation fee · Consultation fees are non-refundable once your intake is submitted. | charged, amount not published |
A charge is disclosed without an amount, so this is a floor. We never count an unpriced charge as zero.
Price
| Term | Per month | Charged today |
|---|---|---|
| Ozempic, month-to-month “Ozempic Starting at $1,399 CONTAINS SEMAGLUTIDE Month-to-month plan Includes: Licensed provider review and ongoing medical oversight Medical Weight-Care Coach for personalized guidance and accountability Tailored dosage adjustments based on your progress and response” source, read September 2, 2026 | Per month$1,399 | Charged today$1,399 |
We earn nothing from this link. WellMedr has no commercial arrangement with Treatment Registry, and its record here is kept to the same standard as every other.
History
- September 2, 2026 — $1,399
- September 3, 2026 — $1,399
- September 2, 2026 — Entry added to the register
Sourcing and terms
| Prescriber | Asynchronous review |
|---|---|
| Cancellation | “You may cancel automatic renewal at any time. Cancellation takes effect when submitted and stops future renewal charges. It does not automatically reverse a payment already processed or an order already accepted by a pharmacy.” |
| Consult fee | Charged, and the amount is not published. Consultation fees are non-refundable once your intake is submitted. |
Not yet checked: pharmacy, states and membership.
Recorded from wellmedr.com. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.
Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.